OTCPK:PTKF.F

Stock Analysis Report

Executive Summary

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia.


Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.


Similar Companies

Share Price & News

How has Kalbe Farma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTKF.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

PTKF.F

-0.5%

US Pharmaceuticals

-1.1%

US Market


1 Year Return

n/a

PTKF.F

6.3%

US Pharmaceuticals

17.8%

US Market

Return vs Industry: Insufficient data to determine how PTKF.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how PTKF.F performed against the US Market.


Shareholder returns

PTKF.FIndustryMarket
7 Day0%-0.5%-1.1%
30 Day0%-1.0%1.5%
90 Dayn/a5.8%6.6%
1 Yearn/a8.8%6.3%20.2%17.8%
3 Yearn/a25.4%16.6%47.5%38.1%
5 Year-10.4%-10.4%29.0%15.1%71.2%52.4%

Price Volatility Vs. Market

How volatile is Kalbe Farma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kalbe Farma undervalued compared to its fair value and its price relative to the market?

24.91x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PTKF.F ($0.12) is trading above our estimate of fair value ($0.1)

Significantly Below Fair Value: PTKF.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PTKF.F is poor value based on its PE Ratio (24.9x) compared to the Pharmaceuticals industry average (21.6x).

PE vs Market: PTKF.F is poor value based on its PE Ratio (24.9x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: PTKF.F is poor value based on its PEG Ratio (3.5x)


Price to Book Ratio

PB vs Industry: PTKF.F is overvalued based on its PB Ratio (4.2x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Kalbe Farma forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTKF.F's forecast earnings growth (7.2% per year) is above the savings rate (1.7%).

Earnings vs Market: PTKF.F's earnings (7.2% per year) are forecast to grow slower than the US market (14.1% per year).

High Growth Earnings: PTKF.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: PTKF.F's revenue (7.9% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PTKF.F's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PTKF.F's Return on Equity is forecast to be low in 3 years time (16.5%).


Next Steps

Past Performance

How has Kalbe Farma performed over the past 5 years?

4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTKF.F has high quality earnings.

Growing Profit Margin: PTKF.F's current net profit margins (11.6%) are lower than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: PTKF.F's earnings have grown by 4.9% per year over the past 5 years.

Accelerating Growth: PTKF.F's earnings growth over the past year (5.7%) exceeds its 5-year average (4.9% per year).

Earnings vs Industry: PTKF.F earnings growth over the past year (5.7%) exceeded the Pharmaceuticals industry 2.4%.


Return on Equity

High ROE: PTKF.F's Return on Equity (16.2%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Kalbe Farma's financial position?


Financial Position Analysis

Short Term Liabilities: PTKF.F's short term assets (IDR11,084.9B) exceed its short term liabilities (IDR2,551.9B).

Long Term Liabilities: PTKF.F's short term assets (IDR11,084.9B) exceed its long term liabilities (IDR906.2B).


Debt to Equity History and Analysis

Debt Level: PTKF.F's debt to equity ratio (4.5%) is considered satisfactory.

Reducing Debt: PTKF.F's debt to equity ratio has reduced from 5.7% to 4.5% over the past 5 years.

Debt Coverage: PTKF.F's debt is well covered by operating cash flow (329.5%).

Interest Coverage: PTKF.F earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: PTKF.F has a high level of physical assets or inventory.

Debt Coverage by Assets: PTKF.F's debt is covered by short term assets (assets are 15.1x debt).


Next Steps

Dividend

What is Kalbe Farma's current dividend yield, its reliability and sustainability?

1.90%

Current Dividend Yield


Dividend Yield vs Market

company1.9%marketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Years2.1%

Current dividend yield vs market & industry

Notable Dividend: PTKF.F's dividend (1.9%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: PTKF.F's dividend (1.9%) is low compared to the top 25% of dividend payers in the US market (3.73%).


Stability and Growth of Payments

Stable Dividend: PTKF.F's dividend payments have been volatile in the past 10 years.

Growing Dividend: PTKF.F's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (47.5%), PTKF.F's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PTKF.F's dividends in 3 years are forecast to be well covered by earnings (46.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

- Vidjongtius (55yo)

2.7yrs

Tenure

0

Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017. He served as Corporate Secretary of PT. Kalbe Farma Tbk. since March 28, 2008 until June 14, 2017. Mr. Vidjongtius ser ...


Leadership Team

NamePositionTenureCompensationOwnership
- Vidjongtius
President Director2.7yrsno datano data
Lukito Gozali
Head of Investor Relations0yrsno datano data
Lanny Soputro
Director of Corporate Human Resource13.1yrsno datano data
Kurniawan Suhartono
Head of Internal Audit Unit6.3yrsno datano data
Bernadus Winata
Independent Director & Corporate Secretary2.7yrsno datano data
Sie Djohan
Director of Corporate Business Development2.7yrsno datano data

6.3yrs

Average Tenure

55yo

Average Age

Experienced Management: PTKF.F's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
- Vidjongtius
President Director2.7yrsno datano data
Bernadus Winata
Independent Director & Corporate Secretary2.7yrsno datano data
Sie Djohan
Director of Corporate Business Development2.7yrsno datano data
Santoso Oen
Commissioner12.1yrsno datano data
Bernadette Ruth Setiady
President Commissioner2.7yrsno data0.075% IDR3.5m
Ferdinand Aryanto
Commissioner12.1yrsno datano data
Djonny Tjahyadi
Director4.8yrsno datano data
Ongkie Tedjasurja
Director9.1yrsno datano data
Lucky Slamet
Independent Commissioner5.8yrsno datano data
Bujung Nugroho
Director5.8yrsno datano data

5.3yrs

Average Tenure

55yo

Average Age

Experienced Board: PTKF.F's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Kalbe Farma Tbk.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Kalbe Farma Tbk.
  • Ticker: PTKF.F
  • Exchange: OTCPK
  • Founded: 1966
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp63.985t
  • Listing Market Cap: Rp4.628b
  • Shares outstanding: 46.88b
  • Website: https://www.kalbe.co.id

Number of Employees


Location

  • PT Kalbe Farma Tbk.
  • Gedung KALBE
  • Jl. Let. Jend Suprapto Kav 4
  • Jakarta
  • Jakarta Raya
  • 10510
  • Indonesia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLBFIDX (Indonesia Stock Exchange)YesCommon SharesIDIDRJan 1992
PTKF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1992
PTKF.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDMar 2010

Biography

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, the company operates Mitrasana Clinics, a health care service; contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe Farma Tbk. is a subsidiary of PT Gira Sole Prima. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 02:45
End of Day Share Price2020/01/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.